CD19 and rheumatoid arthritis: In particular, patients with RA at onset with high percentages of circulating naïve-activated B cells at baseline (>60.0%) were 4 times more likely to achieve CDAI remission after 24 weeks of treatment compared to patients with a low percentage of CD19+/IgD + CD27-.